Health & Biotech
BIG Smiles as Wellnex Life finalises Mr. Bright deal
Health & Biotech
ASX Health Stocks: Inoviq and Doctor Care Anywhere surge over 20pc; CSL welcomes new CEO
Health & Biotech
Stock Insiders: PharmAust’s subsidiary Epichem generates $3.5m in sales in FY2022
Health & Biotech
ASX Health Stocks: Nova Eye faces FDA hurdle in the US, Uscom recognised in China
Health & Biotech
PharmAust banks R&D tax incentive for innovative research as monepantel clinical trials progress
Health & Biotech
ScoPo’s Powerplays: ASX healthcare sector Christmas rally runs out of puff
Health & Biotech
ASX Health Stocks: HITIQ signs two-year deal with UK Rugby Football League
Health & Biotech
ASX Health Stocks: Imagion jumps 20pc after delivering positive Phase 1 results
Health & Biotech
Weed Week: Aussie companies jostle to become the world’s supplier of medicinal cannabis
Health & Biotech
Creso welcomes new US law making it easier to research benefits, effects of medicinal marijuana
Health & Biotech
ASX Health Stocks: NSB files patent in Australia, Cronos ships one-millionth medicinal cannabis unit
Health & Biotech
Dr Boreham’s Crucible: Fisher & Paykel? It’s Kiwi for Rusmid, bro
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.